Concepedia

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, Didier Meulendijks, Geert Frederix, Emma Kienhuis, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L.T. Imholz,

The Lancet Oncology · 2018 · 419 citations · 17 references

DOIFull text

Open access

Concepts

References

17

Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

Paulo M. Hoff, Rafat Ansari, Gerald Batist et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

, , +14

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem, Chris Twelves, Jim Cassidy et al. · Journal of Clinical Oncology · 2001 · 1K citations

, , +14

Population study of dihydropyrimidine dehydrogenase in cancer patients.

M C Etienne, J.-L. Lagrange, O. Dassonville et al. · Journal of Clinical Oncology · 1994 · 432 citations

, , +15

Sample size tables for exact single‐stage phase II designs

Roger A’Hern · Statistics in Medicine · 2001 · 398 citations

, , +16

Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen, Didier Meulendijks, Annemieke Cats et al. · Journal of Clinical Oncology · 2015 · 345 citations · Full text

, , +17